by Paul | 6th October 2026 | News
NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain First patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN London and New York, NY, October 6, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a...
by Paul | 29th September 2026 | News
OKYO demonstrates continued commitment to optometry and ophthalmology London and New York, NY, September 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
by Paul | 9th September 2026 | News
Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain London and New York, NY, September 9, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage...
by Paul | 8th September 2026 | News
London and New York, NY, September 8, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced...
by Paul | 28th July 2026 | News
London and New York, NY, July 28, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj...
by Paul | 27th July 2026 | News
London and New York, NY, July 27, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its...
